Last updated: 2026-09-05 22:26:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Evolus, Inc. (EOLS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $9,30, with a market capitalization of $598,42M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3,86 to $9,31. This page covers its latest market performance, valuation, price trends and company information.
$598,42M | |
$9,05 | |
$39,50 | |
$2,85 | |
$9,05 | |
621,19K | |
-- | |
-- | |
$9,31 | |
$3,86 | |
-- | |
-- |
Evolus, Inc. (EOLS) last closed at $9,05 as of 2026-09-04 23:49:00, unchanged from the previous close of $9,05.
During the latest regular trading session, EOLS traded between $2,85 and $39,50, with a volume of 621,19K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Evolus, Inc. (EOLS) moved from $8,85 to $9,30, representing a gain of 5,13% ($0,45).
The stock traded between $8,97 and $9,31 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 868,52 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 100,0%
EOLS is currently trading at $9,30, placing it 100,0% of the way from its 52-week low of $3,86 to its 52-week high of $9,31. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 353 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Evolus, Inc. (EOLS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.